Login / Signup

Three-day regimen of oseltamivir for post-exposure prophylaxis of influenza in hospital wards: a study protocol for a prospective, multi-center, single-arm trial.

Nobuhisa IshiguroYoichi M ItoSumio IwasakiMiki NagaoHideki KawamuraShinichiro KanaiYoko NukuiKoichi TokudaTakayuki MiyaraHidetoshi IgariKoichi YamadaHiroki ChikumiChiaki SanoRyuji KoikeTetsuya YagiNobuo Murakaminull null
Published in: BMC infectious diseases (2021)
A 3-day regimen of oseltamivir as PEP has advantages over 7- to 10-day regimens in terms of costs, medication adherence and adverse effects. Trial registration The Institutional Review Board of Hokkaido University Hospital for Clinical Research, 015-0518, registered on November 11, 2016. UMIN Clinical Trials Registry, UMIN000024458, disclosed on October 31, 2016. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027881 . Japan Registry of Clinical Trials, jRCTs011180015, disclosed on March 14, 2019. https://jrct.niph.go.jp/latest-detail/jRCTs011180015.
Keyphrases
  • clinical trial
  • phase ii
  • phase iii
  • study protocol
  • open label
  • minimally invasive
  • healthcare
  • double blind
  • randomized controlled trial
  • placebo controlled